Literature DB >> 18250502

Controversies in the management of hyperglycemia in the ELBW infant.

V R Kairamkonda1, M Khashu.   

Abstract

Hyperglycemia is a common problem in newborns undergoing intensive care, especially extremely low birth weight (ELBW) infants. There is a lack of consensus with regard to various aspects of management of neonatal hyperglycemia including definition, optimal management strategy as well as short and long term implications. We reviewed the current evidence in this regard. Recent studies suggest that adequate control of hyperglycemia may be beneficial but long-term implications of hyperglycemia and insulin therapy in the ELBW infants are not known. Awaiting further research, it may be pragmatic to use a more operational definition of hyperglycemia and limit insulin therapy to neonates with high risk of osmolar derangement as per the proposed guideline.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250502

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  Nutritional practices and growth velocity in the first month of life in extremely premature infants.

Authors:  Camilia R Martin; Yolanda F Brown; Richard A Ehrenkranz; T Michael O'Shea; Elizabeth N Allred; Mandy B Belfort; Marie C McCormick; Alan Leviton
Journal:  Pediatrics       Date:  2009-07-27       Impact factor: 7.124

2.  Prematurity disrupts glomeruli development, whereas prematurity and hyperglycemia lead to altered nephron maturation and increased oxidative stress in newborn baboons.

Authors:  Danielle A Callaway; Lisa L McGill-Vargas; Amy Quinn; Jasmine L Jordan; Lauryn A Winter; Diana Anzueto; Edward J Dick; Cynthia L Blanco
Journal:  Pediatr Res       Date:  2018-01-03       Impact factor: 3.756

3.  Permissive hyperglycemia in extremely low birth weight infants.

Authors:  Hye Soo Yoo; So Yoon Ahn; Myung Sook Lee; Young Mi Han; Se In Sung; Yun Sil Chang; Won Soon Park
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.